|
| Trial | Design | Intervention | N | Inclusion Criteria (stage/grade/histology) | Results | Adverse Events |
|
| Adjuvant Trials | | | | | | |
| Jocham et al. (2004) [25] | Prospective, randomized | Autologous renal tumor cells | 558 | pT2–3b pN0–3 M0; Clear and Non-Clear Cell | Improved 5 year and 70 month PFS (HR 1.58, 95% CI 1.05-2.37; HR 1.59, 95% CI 1.07-2.36) | Local skin reactions |
| Wood et al. (2008) [26] | Prospective, randomized | Autologous tumor-derived protein | 819 | cT1b–4 N0 M0, cT(any) N1-2 M0; Clear and Non-Clear Cell | No difference in PFS at 1.9 median year follow-up (HR 0.92, 95% CI 0.729-1.169) | Local skin reactions |
| ARISER, Chamie et al. (2016) [27] | Randomized, Double-blinded, Placebo-controlled | Girentuximab | 864 | pT1b–2 (Fuhrman ≥3), pT3–4 N0, pT(any) N+; Clear Cell | No difference in DFS (HR 0.97, 95% CI 0.79-1.18) or OS (HR 0.99, 95% CI 0.74-1.32 | Toxicity rate 21%, comparable to placebo |
| Neoadjuvant Trial | | | | | | |
| Cost et al (2011) [28] | Retrospective | Sunitinib (12), bevacizumab (9), sorafenib (1), temsirolimus (3) | 25 | T3b+M1 (21) | 25/0 | 12% downstage thrombus level; 4% upstage level; 4% altered surgical strategy |
|
